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Licensed seasonal influenza vaccines induce antibody responses against influenza 
hemagglutinin that are limited in their ability to protect against different strains of 
influenza. Cytotoxic T lymphocytes (CTLs) recognizing the conserved internal 
nucleoprotein (NP) and matrix protein (M1) are capable of mediating a cross-
subtype immune response against influenza. Modified vaccinia virus Ankara 
encoding NP and M1 (MVA-NP+M1) is designed to boost pre-existing T-cell 
responses in adults in order to elicit a cross-protective immune response. We 
examined the co-administration of hemagglutinin (HA) protein formulations and 
candidate MVA-NP+M1 influenza vaccines in murine, avian, and swine models. 
Antibody responses post-immunization were measured by ELISA and pseudotype 
neutralization assays. Here we demonstrate that MVA-NP+M1 can act as an 
adjuvant enhancing antibody (Ab) responses to HA while simultaneously 
inducing potent T-cell responses to conserved internal antigens. We show that this 
regimen leads to the induction of cytophilic Ab isotypes that are capable of 
inhibiting hemagglutination and in the context of H5 exhibit cross-clade 
neutralization. The simultaneous induction of T cells and antibody responses has 




For the past 60 years vaccination has and continues to be the main method 










seasonal influenza vaccines are updated regularly, in over half a century there 
have been few changes in the overall vaccination strategy. It is well established 
that licensed influenza vaccines work by eliciting neutralizing antibodies against 
the surface hemagglutinin (HA) protein, yet these antibodies confer little or no 
protection against distinct subtypes [1]. Subsequently the efficacy of existing 
vaccines is highly dependent on correctly matching vaccine strains with 
circulating influenza strains [2]. Protection rates vary year-to-year and are 
estimated in healthy adults to be between 60-90% when the strains are correctly 
matched [3]. However, a recent meta-analysis assessing the efficacy and 
effectiveness of seasonal influenza vaccines suggests that protection rates may be 
overestimated [4]. Moreover, protection rates in the elderly are even lower despite 
the fact that this demographic accounts for 90% of influenza-related mortality and 
is a key target in vaccination campaigns [4]. There is a vital need to develop more 
effective influenza vaccines and to re-evaluate influenza vaccination strategies 
especially in regards to pandemic preparedness.  
“Universal flu vaccines” that elicit cross-protective immunity have long 
been the goal of researchers [5]. There is abundant evidence, in animal models, 
that CD8
+
 T cells can mediate cross-protective influenza immunity. While there is 
substantially less evidence in humans, a study published in 1983 by McMichael et 
al. demonstrated that CTL activity correlates with reduced influenza viral 
shedding in the absence of antibodies to HA and NA [6]. More recently the results 
from a study by Wilkinson et al indicated that pre-existing CD4
+
 T-cell responses 










severe illness in a human challenge model [7]. Natural influenza infection does 
induce some cross-protective immunity, yet this CD8
+
 T-cell-mediated immunity 
has been shown to be short-lived [8]. Together these studies suggest that a vaccine 
capable of boosting cross-reactive T-cell responses to conserved internal antigens 
of influenza has the potential to modify or prevent disease. modified vaccinia 
Ankara encoding NP and M1 (MVA-NP+M1) is a novel candidate influenza 
vaccine. A Phase I study demonstrated the viral vectored vaccine to be safe, 
immunogenic, and capable of boosting antigen specific CD8
+
 T cells [9]. In a 
Phase IIa vaccination and influenza challenge study, MVA-NP+M1 additionally 
demonstrated clinical efficacy in healthy adult volunteers [10]. A co-
administration regimen could have the advantage of simultaneously inducing cell-
mediated and humoral immunity. Using three animal models, we explored co-
administration of MVA-NP+M1 with various HA protein formulations and 
characterized the immunogenicity of this regimen in mice, chickens, and pigs. 
Our data suggests that MVA-NP+M1 acts as an adjuvant, enhancing Ab responses 
to HA while simultaneously inducing T-cell response to NP and M1. 
 
Results 
MVA-NP+M1 improves the immunogenicity of trivalent inactivated vaccine (TIV) 
in a murine model. 
 To address the limitations of current vaccines, we evaluated the co-
administration of licensed TIV with our candidate T-cell vaccine MVA-NP+M1 










influenza and improve vaccine efficacy. Mice were immunized i.m. with 0.2 g 
TIV with or without 10
6
 plaque forming units (PFU) MVA-NP+M1. Serum IgG 
titers were assayed 2 weeks post-immunization (i.m.x) in response to TIV by 
ELISA. After a single vaccination, mice receiving TIV+MVA-NP+M1 possessed 
significantly higher anti-TIV titers (median 1966 Relative Elisa Units (EUs)) than 
mice receiving TIV alone (median 260 EUs Fig. 1A). This represents > 7-fold 
increase in antibody-titers (Fig. 1A). To ensure that co-administration did not 
interfere with T-cell responses, ex vivo IFN-  ELISPOT responses to a pool of NP 
peptides were measured using splenocytes at 2 weeks post-immunization All mice 
had measurable responses to NP but no significant differences were observed 
between mice receiving MVA-NP+M1 alone (median 160 spot forming units 
(SFUs)) and mice receiving TIV+MVA-NP+M1 (median 154 SFUs, Fig. 1B). 
Together these data suggested that co-administration enhances humoral responses 
to TIV while eliciting potent cellular responses to conserved internal antigens. 
 Having observed a clear difference in the magnitude of the antibody 
response when TIV is co-administered with MVA-NP+M1, dose escalation and 
de-escalation experiments were carried out. C57BL/6 mice were immunized i.m. 
with a range of TIV doses and serum IgG titers were assayed 2 weeks post-
immunization to TIV by ELISA. At all doses of TIV mice receiving TIV+MVA-
NP+M1 possessed significantly higher anti-TIV antibody titers than mice 
receiving TIV alone (Fig. 1C).  Moreover, an increased dose of TIV in the co-
administration group lead to increased antibody titers (1 g and 1.5 g 










recombinant H1 HA (A/California/04/09) measured by ELISAs mirrored those 
observed with TIV indicating that serum antibody responses were specific to HA 
components of TIV (data not shown).  
   
Longevity of Ab responses 
To further investigate the immunogenicity of TIV+MVA-NP+M1 co-
administration, we sought to establish whether enhanced Ab responses are 
maintained over time. Ab responses induced by co-administration were measured 
at 2, 8, 16, and 24 weeks post-immunization for 4 doses of TIV. For all treatment 
groups peak Ab response was seen at 8 weeks post-immunization (Fig. 2A-D).  
For mice immunized with 0.2 g, 1 g, and 1.5 g TIV Ab responses in mice 
receiving TIV+MVA-NP+M1 were significantly higher than mice receiving TIV 
alone at all time points (Fig. 2B-D). Taken together these data suggest that MVA-
NP+M1 co-administration adjuvants the Ab response to TIV and this enhanced 
Ab response persists up to 6 months post-immunization At 2 weeks post-
immunization, anti-TIV Ab titers for 1.5 g TIV+MVA-NP+M1 (median 5904 
EUs, Fig. 2D) were significantly higher than both 0.2 g TIV+MVA-NP+M1 
(median 3030 EUs, Fig. 2B) and 1 g TIV+MVA-NP+M1 (median 2811 EUs, 
Fig. 2C). However, there was no significant difference in peak Ab titers achieved 
at 8 weeks at these 3 doses (medians 5087, 6755, 5574 EUs respectively, Fig. 2B-
D). This observation also held at 16 weeks and 24 weeks post-immunization (Fig. 
2B-D). These results indicate that we have reached maximal titers achievable with 










antigen needed to achieve high Ab titers. To evaluate IgG Ab isotypes induced by 
TIV+MVA-NP+M1 co-administration, isotype ELISAs were carried out using the 
serum of mice immunized with two different doses of TIV or TIV+MVA-NP+M1 
at 8 weeks post-immunization when peak Ab titers are observed. IgG2a/IgG1 
ratios were calculated and mice immunized with TIV+MVA-NP+M1 had 
significantly higher ratios of IgG2a/IgG1 as compared to mice immunize with 
TIV alone (Supporting Information Fig. S1). 
The adjuvanting effect of the candidate vaccine MVA-NP+M1 relies on both local 
and systemic factors 
 In the data presented thus far, TIV and MVA-NP+M1 were mixed and 
administered in the same syringe. In order to dissect the underlying mechanism it 
is useful to examine whether this co-formulation is necessary for co-induction of 
cellular and humoral responses. To determine the optimal administration regimen 
we employed 3 different administration routes: mixed, separate flank, and 
adjacent (Materials and Methods). Serum IgG titers were assayed in response to 
TIV by ELISA at 2 weeks post-immunization Mice immunized with 0.2 g TIV+ 
MVA-NP+M1 in separate flanks possessed significantly higher titers of anti-TIV 
Ab than mice immunized with 0.2 g TIV alone (medians 596 and 178 EUs 
respectively, Fig.3A). Similarly, mice immunized with both TIV+MVA-NP+M1 
via the adjacent route (Materials and Methods) possessed significantly higher 
titers of anti-TIV Ab than mice immunized with 0.2 µg TIV alone (medians 1857 










regimens at 2 weeks post-immunization there was no significant difference in 
titers between the adjacent and mixed administration route (medians 1857 and 
1880 EUs respectively, Fig.3A). However, Ab titers for mice immunized with 
TIV+MVA-NP+M1 in separate flanks were significantly lower than mice 
immunized adjacently (medians 596 and 1857 EUs respectively, Fig.3A) and via 
the mixed regimen (medians 596 and 1880 EUs respectively, Fig.3A). Therefore 
while an enhanced Ab response was observed when mice received both vaccines 
in separate flanks (Fig.3A) these titers were 3-fold lower than the titers reached 
when mice received both vaccines in the same flank (Fig.3A). Therefore 
magnitude of the Ab response is influenced not only by local, but additionally by 
systemic factors.  
Class-switched antibody responses can be initiated through the 
extrafollicular or the germinal center pathway[11]. Having determined that 
TIV+MVA-NP+M1 co-administration leads to an enhanced Ab response that 
persists over time, we next evaluated differences in vaccination regimens at the 
germinal center level. Mice immunized with TIV or TIV+MVA-NP+M1 were 
sacrificed at days 7, 9, and 11; lymph nodes were isolated and single cells were 







Supporting Information Fig. S5). There were significantly higher percentages of 
germinal center B cells in mice receiving TIV+MVA-NP+M1 as compared to TIV 











Hemagglutination Inhibition Assay and Challenge Studies 
With evidence that our co-administration regimen induces high levels of 
serum IgG antibodies specific to the homologous TIV components, we 
additionally sought to evaluate whether these serum antibodies exhibited 
hemagglutination inhibition (HAI) activities. The ability of serum antibodies to 
inhibit hemagglutination is considered a functional antibody response. We 
determined homologous HAI titers against all three influenza virus components of 
the 2010-2011 TIV using serum samples collected at 2 weeks post-immunization 
(Table 1). More serum samples from mice receiving TIV+MVA-NP+M1 
displayed intact HAI responses than mice receiving TIV alone (Table 1, where an 
intact response is defined as HAI  20). Most serum samples failed to react with B 
component (B/Brisbane/60/08) (Table 1). When geometric mean titers were 
calculated against each individual virus, HAI titers for mice receiving TIV+MVA-
NP+M1 were significantly higher than mice receiving TIV alone for 
A/California/07/09 and A/Perth/16/09 viruses (Table 2). These results 
demonstrate that functional antibodies are induced by the co-administration 
regimen and serum antibodies from mice receiving TIV+MVA-NP+M1 vaccines 
display greater HAI activities. We then went on to conduct homologous influenza 
virus challenge experiments to determine the relative protective efficacy of the co-
administration regimen. Mice were immunized with 0.2 µg TIV or 0.2 µg 
TIV+MVA-NP+M1 and challenged by intranasal administration with 
A/England/195/09 (H1N1) six months after vaccination. Mice receiving TIV-










(Fig.3C). Survival rates for naïve mice were identical to mice immunized with 
TIV only (n=3), and while the co-administration group trended toward increased 
survival (n=6) the difference was not statistically significant (Fig.3D). 
 
Co-administration with H5 HA in Mice  
Human infections with highly pathogenic avian influenza (HPAI) viruses are 
associated with a high risk of death and considering that most of the world’s 
population is immunologically naïve, there is a pressing requirement to develop 
an H5N1 vaccine [12]. Many difficulties have been encountered in the 
advancement of H5N1 vaccines. Protein based vaccines have proven to be poorly 
immunogenic and potent adjuvants or high doses of protein are needed to elicit 
sufficient antibody titers [13-16]. Moreover, H5N1 viruses have diverged 
considerably into distinct clades and subclades, making cross-clade protection an 
important criterion for a potential vaccine candidate [17]. The results presented 
here suggest that MVA-NP+M1 co-administration can enhance antibody 
responses and reduce the amount of antigen required to induce maximal antibody 
titers, making it a promising vaccine candidate in the context of H5N1 vaccine 
initiatives. We sought to assess whether MVA-NP+M1 could improve the 
immunogenicity of recombinant H5 HA protein. C57BL/6 mice were immunized 





MVA-NP+M1. Serum IgG titers were assessed 2 weeks after 
each immunization and at 8 weeks following the second i.m.x to H5 HA derived 










NP+M1 possessed significantly higher titers of antibodies as compared with mice 
vaccinated with H5 only (Fig.4A), indicating that MVA-NP+M1 co-
administration is capable of enhancing Ab responses to poorly immunogenic H5 
HA. We next sought to evaluate the functional capacity of these antibodies and 
the breadth of response. One way to achieve this in the context of HPAI viruses is 
utilization of pseudotype virus neutralization assays. This technique has been used 
extensively to study and quantify neutralizing antibodies targeting HAs and is 
particularly advantageous as it is able to assess antibodies directed to both the 
globular head and conserved stem regions of HA[5]. We tested the homologous 
and cross-clade neutralization activity of mouse antisera using H5 lentiviral 
pseudotypes at the peak of the Ab response.  Mice immunized with H5+MVA-
NP+M1 generated significantly higher titers of neutralizing antibodies against 
A/VN/1203/04 than mice immunized with H5 protein alone (Table 3). Moreover, 
this co-administration regimen resulted in significantly higher titers of cross-clade 
neutralizing Abs, suggesting an increase in the breadth of the humoral response 
(Table 3).  Enhanced antigen-specific T-cell responses offer one possible 
explanation for the observed increase in the magnitude and breadth of the humoral 
response. To test this hypothesis ex vivo IFN-  ELISPOT responses to H5 HA 
were measured using splenocytes at 2 weeks post-1
st 
immunization Mice receiving 
H5+MVA-NP+M1 displayed significantly higher response to H5 HA than 
animals immunized with H5 only (medians 170 and 13 SFUs respectively, 
Fig.4B). Surface and intracellular staining indicated the majority of IFN- -
producing T cells to be CD4
+ 











Co-administration with H7 HA in Chickens 
We next sought to test this vaccine in relevant animal species. HPAI of the H5 
and H7 subtypes remain a constant concern in the world poultry industry. This has 
lead the World Organization for Animal Health and the Food and Agricultural 
Organization of the United Nations to recommend vaccination of poultry [18, 19]. 
Several viral vectors expressing HA constructs have been shown to be 
immunogenic and protective against HPAI challenge [18]. To investigate this 
regimen and MVA-NP+M1 co-administration, specific pathogen free (SPF) 
outbred Light Sussex chickens were vaccinated in ovo (io) with 1x10
9
 infectious 
units (IU) of AdHu5-NP+M1 (Materials and Methods). At 3 weeks post-hatch 
chickens were boosted with either 10 µg A/Netherlands/219/03 (H7) HA or 10 µg 
H7 HA + 1x10
7
 PFU MVA-NP+M1. One group was not primed io and only 
received 10 µg H7 HA + 1x10
7
 PFU MVA-NP+M1 at 3 weeks post-hatch. Naïve 
birds served as negative controls. Serum IgG titers were measured at 3 weeks 
post-prime, and 1, 2, 3 and 4 weeks post-boost against H7N7 HA by ELISA. 
Serum from individual birds was pooled according to administration group. Post-
boost, chickens receiving AdHu5-NP+M1 prime and H7 HA+MVA-NP+M1 
boost displayed the highest Ab titers (Fig.4C). Interestingly, chickens receiving 
only one H7 HA+MVA-NP+M1 boost displayed higher Ab titers than birds 
receiving AdHu5-NP+M1 prime followed by an H7 HA protein boost (Fig.4C).  
Ex vivo IFN-  ELISPOT responses to a pool of NP+M1 peptides were measured 










and H7 HA +MVA-NP+M1 boost had significantly higher T cell responses 
compared to AdHu5-NP+M1/HA and nil io/MVA-NP+M1+H7 HA (medians 
805, 29, 178 SFUs respectively; Fig.4D). Taken together these data provide 
preliminary evidence in chickens MVA-NP+M1 co-administration is capable of 
eliciting potent T-cell responses and simultaneously increasing Ab responses to 
H7 HA. 
 
Co-administration with H5 in Pigs 
Although swine are utilized as an influenza animal model less frequently than 
mice and ferrets, pigs are a clinically relevant large animal species for studying 
human influenza viruses as they are natural reservoirs for H1N1 and H3N2 
viruses[20]. To test our MVA-NP+M1 co-administration regimen outbred pigs 
(Sus scrofa, n=18 total, 6 per group) were immunized i.m. in a heterologous 
prime-boost regimen with a 4 weeks interval between immunization Animals 
were randomly allocated to one of three groups: (i) were primed with 10 µg H5 
HA (A/duck/Hunan/795/02) and boosted with an identical amount of protein; (ii) 
primed with ChAdOx1-NP+M1 and boosted with MVA-NP+M1; or (iii) primed 
with 10 µg H5 HA and ChAdOx1-NP+M1 and boosted with H5 HA and MVA-
NP+M1. Serum IgG titers were measured at D0, D28, D35, D42 and D56 by 
ELISA. The peak antibody response was observed on D42 (2 weeks post-boost) 
and we assessed neutralization activity of antisera from this time point in 
pseudotype neutralization assays. Although no significant differences were 










H5HA+ChAdOx1/H5HA+MVA (Fig.4E), animals in the co-administration group 
displayed significantly higher titers of neutralizing Abs against 4 out of 5 
lentiviral pseudotypes tested (Table 4). As with the H5 HA co-administration data 
in mice, these results indicate that co-administration with viral vectors increases 
the breadth of the Ab response. Peripheral blood mononuclear cell (PBMC) 
responses to NP and M1 were measured by IFN-γ ELISPOT. All pigs displayed 
measurable responses to NP and M1 peptide pools following boost and peak T-
cell responses were observed 7 days post-boost (D35). At the peak of the response 
the two groups of animals immunized with viral vectors possessed significantly 
higher T-cell responses than animals immunized with protein only (Median 134, 




  Innovative vaccination strategies offer a promising way forward in the 
global effort to manage seasonal and pandemic influenza infections. In this study 
we investigated the administration of our candidate MVA-NP+M1 vaccine with 
various HA protein formulations in three animal species. With the exception of 
live attenuated influenza vaccines (LAIV), almost all seasonal vaccines are 
preparations of inactivated antigen which are limited in their ability to protect 
against different subtypes and strains of influenza. The morbidity and mortality 
associated with influenza make the improvement of preventative health-care 










evidence, in humans, that T cells can limit the severity of influenza-associated 
illness and reduce viral shedding [7, 10]. Poxviral vectors are known to generate 
potent T-cell responses and MVA-NP+M1 has proven to be highly immunogenic 
in Phase I and Phase IIa trials [9, 10]. An influenza vaccination platform capable 
of generating both cellular and humoral responses has the potential to improve 
vaccine efficacy and provide protection in pandemic situations. The use of 
poxviruses as an adjuvant for protein has previously been reported in a hepatitis B 
mouse model [21]. We assessed a similar strategy in the context of influenza 
vaccine. Although previous reports have demonstrated that priming with internal 
antigens can increase anti-HA responses up subsequent influenza infection [22, 
23], here we employed a distinct vaccination strategy. The present analysis 
establishes that a single co-administration of MVA-NP+M1 in influenza naïve 
animals is able to improve the immunogenicity of licensed influenza vaccines by 
simultaneously enhancing Ab responses against surface proteins and generating 
cellular responses to conserved internal antigens. 
 We have shown that co-administration of TIV and MVA-NP+M1 in mice 
leads to the induction of Ab responses that are maintained over time. Protein-in-
adjuvant vaccine formulations are often used to induce high and sustained Ab 
responses and we suggest that MVA-NP+M1 acts as an adjuvant by enhancing the 
humoral response while limiting the amount of antigen needed to achieve 
maximal Ab titers (Fig. 2B-D).  
 Having established that MVA-NP+M1 enhances B-cell responses we 










induces a qualitatively distinct humoral response. We examined B-cell responses 
at the germinal center level in draining lymph nodes and went on to characterize 
anti-TIV antibodies. Mice immunized with TIV+MVA-NP+M1 showed 
significantly higher percentages of germinal center B cells in the draining lymph 
nodes (Fig.3B), suggesting that the observed difference in serum antibody titers 
may be due to enhancement of the germinal center pathway. Interestingly an 
increased antibody response was observed when MVA-NP+M1 and TIV were 
administered in separate limbs, although the highest antibody titers were achieved 
when the two vaccines were given in the same limb (Fig.3A).  
Consistent with previous reports on viral vector vaccination regimens, our 
results indicated a trend toward increased titers of IgG2a in mice receiving 
TIV+MVA-NP+M1 as opposed to TIV alone (Supporting Information Fig. S1). 
Moreover, IgG2a/IgG1 ratios were significantly higher in mice receiving MVA-
NP+M1 than mice receiving TIV alone (Supporting Information Fig. S1). In mice 
Th-1 responses are dominated by IgG2a and this isotype is thought to exert the 
strongest effector functions by activating complement, participating in Ab-
dependent cellular inhibition and phagocytosis [24]. We employed HAI assays 
and challenge experiments to assess the functional and protective capacity of 
antibodies induced by the co-administration regimen. Mice vaccinated with 
TIV+MVA-NP+M1 displayed greater HAI activity (Tables 1&2), and showed a 
trend toward increased survival following a homologous challenge (Fig.3D). 
These findings provide evidence that this approach potentiates a functional 










 HPAI outbreaks remain a challenge for both animal and public health. To 
assess the ability of MVA-NP+M1 to increase responses to H5 and H7 subtypes 
we examined co-administration of MVA-NP+M1 with H5 A/VN/1203/04 in 
mice, H7 A/Netherlands/219/03 in chickens, and H5 A/duck/Hunan/795/02 in 
pigs. Co-administration of H5 in mice was capable of significantly increasing Ab 
responses over protein vaccination alone (Fig.4A). A crucial requirement of H5 
vaccines is the ability to induce cross-clade protection against divergent H5N1 
strains. Previous studies with H5-based vaccine report the induction of cross-cross 
clade neutralizing antibodies [13, 15, 16]. We utilized pseudotype neutralization 
assays to evaluate the functional capacity of antibodies. This technique has proven 
to be a powerful tool that allows for the assessment of antibodies directed to both 
the head and stem regions of HA. We observed cross-clade neutralizing 
antibodies in mice immunized with MVA-NP+M1 at significantly higher titers 
than animals immunized with protein alone (Table 3).  To gain further insight into 
the underlying mechanism responsible for the adjuvant effect, we examined T-cell 
responses to HA and found co-administration significantly increased the 
frequency of HA-specific T cells (Fig.4B). Vaccination of poultry offers one 
approach for control of avian influenza viruses and several studies have examined 
the use of viral vectors in this context. In chickens, Adenoviruses expressing H5 
HA or H7 HA have demonstrated protection from HPAI challenge when 
administered io and in a homologous prime-boost regimen [18, 19]. Similarly a 
single immunization with MVA expressing H5 HA also conferred protection 










heterologous prime-boost regimen to increase responses to H7 HA for the first 
time in chickens. Although this study did not go on to challenge the vaccinated 
chickens, a recent challenge study evaluating an identical prime-boost regimen 
administered without protein demonstrated reduced cloacal virus shedding [26]. 
Our data indicated a trend toward increased Ab responses in birds receiving H7 
+MVA-NP+M1 (Fig.4C) and a robust T-cell response to conserved internal 
antigens (Fig.4D). While further studies will be necessary to assess the ability of 
these regimens in a challenge model, our data in combination with the recent 
proof of concept study suggest that this vaccination regimen could be efficacious 
in chickens.  
  Despite being infrequently utilized in influenza studies, pigs are a 
valuable animal model as influenza viruses are enzootic in pigs [27]. In this study 
we assessed the immune response in outbred pigs following a heterologous prime-
boost regimen. In one treatment group, H5 HA protein was administered with 
viral vectors at both prime and boost immunizations. After boosting, we detected 
T-cell responses to NP+M1 peptide pools in PBMCs in the two treatment groups 
that received viral vectors (Fig.4F). These T-cell responses peaked 7 days post-
boost and were significantly higher than in animals that received two inoculations 
of protein only (Fig.4F). Similar to the data in chickens, pigs in the co-
administration group (H5HA+ChAdOx1/H5HA+MVA) displayed a trend toward 
increased Ab titers at the peak of the response (D42, Fig.4E). While the difference 
between this group and animals receiving H5 HA protein only was not significant, 










antibodies against four H5 lentiviral pseudotypes (Table 4). Thus in both swine 
and murine models we found Abs that exhibited broad patterns of neutralization 
against different H5 pseudotypes representative of antigenically divergent clades.  
The main finding of this study is that that co-administration of HA protein 
and MVA-NP+M1 can simultaneously induce both strong humoral and cellular 
responses in a mouse model. Our results provide preliminary evidence that MVA-
NP+M1 also acts in chickens and pigs as an adjuvant to boost B-cell responses. 
The improved immunogenicity of co-administration is especially promising as the 
efficacy of licensed vaccines is particularly poor in the elderly and 
immunocompromised individuals, whereas MVA-NP+M1 is highly immunogenic 
in older adults [28]. This approach of combining poxviral vectors with licensed 
vaccines could improve the efficacy of seasonal influenza vaccines and play an 
important role in limiting the severity of global pandemics. 
 
Materials and Methods 
Murine immunizations 
All procedures were performed in accordance with the terms of the United 
Kingdom Animals (Scientific Procedures) Act Project License and were approved 
by the University of Oxford Animal Care and Ethical Review Committee. Six-
week-old C57BL/6 (H-2
b
) mice (Harlan Laboratories, Oxfordshire, UK) were 
anesthetized prior to immunization with Isoflo (Abbot Animal Health). All 










administration routes were used in the experiments described in this study. For the 
regimen designated “Mixed” TIV and MVA-NP+M1 were co-formulated prior to 
injection and administered in the same syringe. In the “Separate flank” regimen, 
mice received TIV in one flank and MVA-NP+M1 was administered in the 
opposite flank. Finally, in the “Adjacent’ administration route TIV and MVA-
NP+M1 were administered in the same flank but in separate syringes (i.e. side-by-
side). Immunization doses and intervals are explained in the text and figure 
legends. With the exception of the germinal center staining, immune responses 
were assayed at 2, 8, 16, and 24 weeks post-immunization.  
Pig immunizations 
Outbred male (Sus scrofa) pigs were conventionally reared at the Central 
Veterinary Institute, part of Wageningen University & Research (Lelystad, The 
Netherlands). Pigs were 8 weeks of age at the initiation of the study, weighing 
approximately 20±5kg. Prior to the study, all pigs were bled and shown to be 
negative for influenza exposure by an NP ELISA.  The pigs (n=6 per group, 3 
groups) received two immunizations 4 weeks apart (D0 and D28). On D0 pigs 
received H5 HA only (A/duck/Hunan/795/02) (group 1), ChAdOx1-NP+M1 
(group 2), or H5 HA and ChAdOx1-NP+M1 (group 3). Four weeks later groups 
were boosted with either H5 HA (A/duck/Hunan/795/02) (group 1), MVA-
NP+M1 (group 2), or H5 HA and MVA-NP+M1 (group 3). The vaccines were 
supplied separately and in the group receiving both H5 HA and a viral vector the 
two injections were administered adjacently in the same limb. Blood samples 










at Lelystad were kept at room temperature (RT) and shipped overnight to the 
Pirbright Institute (Compton Laboratory, UK). All animals were sacrificed on 
D56 and post-mortem spleen and bronchiolar lavage samples were collected.  
Swine experiments were approved by the experimental commission of CVI. CVI 
is authorized to perform animal studies by permission of the Dutch Ministry of 
Agriculture. 
Chicken immunizations 
Specific pathogen free (SPF) outbred Light Sussex chickens were supplied as 19-
day-old embryos by the Poultry Production Unit of the Pirbright Institute. Birds 
were maintained post-hatch in SPF containment and experimental procedures 
were carried out in accordance with IAH Ethical Review and UK Home Office 
requirements.  Vaccination regimens were: Ad-NP+M1 io, HA post-hatch (n=5); 
no treatment io, MVA-NP+M1 and HA post-hatch (n=5); Ad-NP+M1 io, MVA-
NP+M1 and HA post hatch (n=5). Naïve birds served as controls (n=4). At 3 
weeks post-hatch MVA-NP+M1 was administered into the pectoral muscle, with 
or without H7 HA (A/Netherlands/219/03).  For the co-administration group 
MVA-NP+M1 and HA were mixed prior to administration.  Blood samples were 
taken by wing vein puncture pre-boost and at weekly intervals post-boost for 4 
weeks.   
Viral vectors and protein vaccines 
The poxviral vector administered in this study is a recombinant Modified 
Vaccinia Virus Ankara (MVA-NP+M1) expressing influenza A NP fused to 










reading frame (NP+M1). The design and manufacturing of MVA-NP+M1 has 
been previously described [9]. MVA-NP+M1 was administered at 10
6
 PFU i.m. in 
mice, 1.5 x 10
8
 PFU in pigs and 10
7
 PFU in chickens. Pigs received 10 g of H5 
HA A/duck/Hunan/795/02 (NIH Biodefense and Emerging Infection Research 
Resource Repository, NIAID, NIH). Chickens were immunized with 10 g of 
recombinant H7 HA from A/Netherlands/219/03 (H7) per bird (BEI Resources, 
Manassas, VA). Mice in H5 HA co-administration studies were immunized twice 
with 10 g of recombinant A/VN/1203/04 (BEI Resources, Manassas, VA), with 
a 3 weeks interval between each administration. Recombinant AdHu5 and 
ChAdOx1 expressing the NP+M1 constructs were generated in an identical 
manner to previously described recombinant adenoviral vectors [29, 30]. For 
chicken immunization, AdHu5-NP+M1 was administered io at 1 x 10
9
 infectious 
units (IU) per embryo at day 19 of embryonic development. Pigs received 5 x 10
10 
vp ChAdOX1-NP+M1 in the hind leg i.m.. Unadjuvanted Fluarix (GSK, 
Dresden,Germany) or Fluzone (Sanofi-Pasteur) were used for all TIV 
vaccinations at the doses described in the text and figure legends.  
Standardized ELISA 
To detect total IgG to TIV, Nunc Maxisorp plates were coated at a concentration 
of 0.75 g/mL TIV and left overnight at 4 C. For H5 and H7 HA ELISAs plates 
were coated at a concentration of 2 g/mL with H5 HA (A/Vietnam/1203/04) or 
H7 HA (A/Netherlands/219/03). The following day, plates were washed 6x with 
PBS containing 0.05% Tween 20 (PBS/T). Plates were blocked with 100 L/well 










Dilution series of serum samples (2-fold from 1:500) were added to the plates for 
2 h at RT. A reference serum was used to generate at standard curve. The 
reference sera for mice consisted of pooled sera from mice immunized with 
TIV+MVA-NP+M1. For chickens, sera from birds previously infected with 
A/turkey/England/1977 H7N7 were used. A standard positive serum sample and a 
naïve serum sample were added as controls for each assay. Plates underwent a 
further wash step before the addition of the either alkaline phosphatase conjugated 
goat anti-mouse IgG (1:5000, Sigma), or rabbit anti-chicken IgY (1:5000; Sigma) 
for 1 h at RT. Bound antibodies were detected by adding p -nitrophenylphosphate 
substrate (pNPP, Sigma) diluted in diethanolamine buffer (Fisher Scientific). 
Plates were allowed to develop until the 5
th
 dilution of standard reference serum 
(1:1600) reached an OD405 of 1 using an ELx800 microplate reader (Biotek). This 
point was defined as 1 relative antibody unit and units were read off of the 
standard curve similar to published methodology[31]. Samples were diluted to fall 
on the linear part of the standard curve.  
Swine Endpoint Titers ELISAs 
To determine H5 HA-specific IgG titers, 96 well plates were coated for 1 hr at RT 
with H5 HA from A/duck/Hunan/795/02 (1 µg/ml in carbonate buffer, pH 9.6). 
Plates were washed 5 times with PBS/T and blocked with PBS containing 0.5% 
Tween 20 and 4% skimmed milk (blocking buffer) for 1 hr. After five washes, 
100 l per well blocking buffer or 1:3 serial dilutions of sera (starting from 1:50) 
were added and incubated for 1 h at RT. Plates were subsequently washed before 










for 1 hr at RT. After washing, 100 l 3,3’,5,5-tetra-methyl benzidine (TMB) 
substrate was added and the reaction was stopped after 10 min by the addition of 
50 l of 1.2M H2SO4. The optical density (OD) values at both 450 and 630 nm 
were read for each well on a SpectraMAX 250 plate reader at dual wavelength. 
Anti-ovalbumin IgG titers (mean of duplicates) were calculated as follows: the 
log10 OD against log10 sample dilution was plotted and a regression analysis of the 
linear part of this curve allowed calculation of the endpoint titer with an OD of 
twice the background. 
Mouse Challenge Model 
Six months following immunization with either 0.2 g TIV (n=7) or 0.2 g 
TIV+MVA-NP+M1 (n=7) mice were challenged with A/England/195/2009 
(H1N1) influenza virus along with naïve controls (n=7). Mice were anesthetized 
with 100 µL of ketamine/dormitor® administered via intraperitoneal injection 
(i.p.). Virus was inoculated intranasally in a volume of 50 µL and each mouse 
received 1x10
4 
PFU. Mice were monitored daily for 14 days for clinical disease, 
symptoms including weight loss, piloerection, and reduced motility; animals with 
no weight loss were considered to have failed challenge. A 25% reduction in 
bodyweight was defined as a humane endpoint and animals meeting this criterion 
were euthanized.  
Pseudotype Neutralization Assay 
Influenza lentiviral pseudotypes for H5N1A/Vietnam/1203/2004 
(A/VN/1203/04), A/Hong Kong/213/2003 (A/HK/213/03), 










A/Anhui/1/2005 (A/AN/1/05), expressing firefly luciferase were produced at the 
Viral Pseudotype Unit. Pseudotype neutralization assays [32] . Briefly, mouse and 
pig serum samples were serially diluted twofold from 1:40 in a 96-well flat 
bottom plate. A comparable amount of each pseudotype (giving an output of 
500,000 Relative Light Units) was incubated with sera for 1 h at 37°C before the 
addition of 1x10
4
 293T cells per well. Luciferase activity was measured 48 h later 
and IC50 neutralization titer was determined as the serum dilution yielding a 50% 
reduction in luciferase activity as compared to control wells with virus alone.  
Hemagglutinin Inhibition Assay 
The HAI assays were performed in V-bottom microtiter plates with 0.75% turkey 
erythrocytes as previously described [33]. To assess the geometric mean titers, 
negative samples were assigned a value of half the minimum detectable amount.  
Murine Ex-vivo IFN-  ELISPOT 
IFN-  ELISPOTs were carried out using splenocytes as previously described[34]. 
To gauge NP+M1 responses, 15-20-mer peptides overlapping by 10 amino acids 
spanning the carboxy-terminal half of the NP insert were used to stimulate 
splenocytes at a final concentration of 5 g/ml. Previous experiments using 
peptides spanning the entire NP+M1 insert determined that the majority of 
responses were directed against the carboxy-terminal half of NP. To measure HA 
responses, 20-mer peptides overlapping by 10 amino acids spanning the entire 
length of H5 HA (VN/1203/04 Accession ABW90125.1) were used to stimulate 










Pig ex vivo IFN-   ELISPOT 
IFN-   ELISPOTs were completed using PBMCs as previously described [27]. 
15- 20-mer peptides overlapping by 10 amino acids spanning the entire NP+M1 
insert were used to stimulate PBMCs at a final concentration of 10 g/ml. 
Chicken ex vivo IFN-   ELISPOT 
Post mortem spleens were prepared and IFN-γ ELISPOT was carried out as 
described previously [26]. Overlapping pools of 15- to 20-mer peptides spanning 
the entire NP+M1 insert were used to measure T cell responses. Pools of 
irrelevant peptides were used to control for background responses.  
Preparation of cell suspensions for Germinal Center Staining 
Draining inguinal lymph nodes were harvested on days 7, 9, and 11 post-
immunization. Lymph nodes were passed through a 70 m cell strainer (Falcon) 
in PBS. Cells were spun down and resuspended at 10
7
 cells/mL, before 100 L 
were plated in a round bottom 96-well plate.  
Flow Cytometry and Germinal B Cell Center Staining 
Conjugated Abs anti-mouse B220 PerCP-Cy7, CD95-PE and GL-7-FITC were 
obtained from eBioscience. C57BL/6 mice were immunized as previously 
described. On days 7, 9, and 11 inguinal draining lymph nodes were harvested 
and processed as described above. Surface staining was carried out for 30 min at 
4 C in the dark on 1x10
6 
cells in PBS/BSA (0.05% BSA). Cells were spun down 










Sciences, Franklin Lakes, NJ) and analyzed with FlowJo software (Treestar, Inc. 
Ashland,OR) 
Statistical Analysis 
Statistical analysis was carried out using Prism 5 software (GraphPad, La Jolla, 
CA, USA). For nonparametric data, a Mann-Whitney U test was used to compare 
two groups. One-way ANOVA or Kruskal-Wallis tests were used to compare 2 or 
more groups. A p value <0.05 was considered significant throughout. 
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 Figure 1. Co-administration of MVA-NP+M1 can affect the immune response to 
inactivated influenza vaccine. Mice were immunized i.m. with 0.2 µg TIV  
MVA-NP+M1 via the mixed administration route (Material and Methods). Total 
IgG titers in the serum were measured to TIV by standardized ELISA. “MVA” is 
used to abbreviate “MVA-NP+M1”. (A) IgG titers measured at 2 weeks post-
immunization. *** p<0.001 by Mann-Whitney test. (B) T-cell responses assayed 
by ex vivo IFN-γ ELISPOT in splenocytes at 2 weeks post-immunization are 
shown. Cells were stimulated with NP peptide pools. ** p<0.01 ***p<0.001 by 
Kruskal-Wallis test. (A, B) Symbols represent individual mice and bars represent 
medians. (C) Dose escalation study. Total IgG titers in the serum were measured 
to TIV by standardized ELISA. The dotted line indicates threshold for responses 
above background.  Data are shown as median + interquartile range of 5 (0.004, 
0.02, 0.1 and 1 μg doses), 10 (1.5 μg dose), 15 (0.04 μg dose) and 20 (0.2 μg 
dose) mice per group.  (A-C) Data shown are pooled from three independent 











Figure 2. Longevity of vaccine induced IgG responses. Mice were immunized i.m. 
with TIV  MVA-NP+M1. For mice receiving TIV+MVA-NP+M1, vaccines were 
mixed prior to administration. Total IgG titers in the serum were measured to TIV 
by standardized ELISA at 2, 8, 16, and 24 weeks post-immunization for (A) 0.04 
µg TIV ± MVA-NP+M1,  (B) 0.2 µg TIV ± MVA-NP+M1, (C) 1 µg ± MVA-
NP+M1.  and Panel C(D): 1.5 µg ± MVA-NP+M1. The dotted line indicates 
threshold for responses above background.  Data are shown as median + 
interquartile range for 5 mice per group and are representative of one experiment. 











Figure 3. Optimizing the co-administration regimen and homologous challenge. 
Mice were immunized i.m. with 0.2 μg TIV+ MVA-NP+M1 via three separate 
administration routes (Separate flank, Adjacent, and Mixed as described in 
Materials and Methods). Total IgG titers were measured in the serum in response 
to TIV by ELISA at 2 weeks post-immunization. (A) Comparison of median IgG 
levels in response to TIV by ELISA at 2 weeks. Each symbol represents 
individual mice and the bars represent medians; data shown are pooled from three 
experiments performed.  The dotted line indicates threshold for responses above 
background. A Kruskal-Wallis test with Dunn’s multiple comparison posttest was 
used to determine statistical significance *p<0.05, ***p<0.001(B) Mixed co-
administration of TIV and MVA-NP+M1 affects the percentage of germinal 
center B cells in the draining lymph node. Germinal center B cells in the draining 
inguinal lymph nodes were examined at 7, 9, and 11 days post-immunization by 
flow cytometry. Lymphocytes were gated on B220
hi
 cells and subsequently 
analyzed for expression of CD95-PE and GL-7-FITC. Data are shown as median 
+ interquartile range of 4 mice per time point and are from one experiment 
representative of two performed. *p<0.05 by Mann Whitney test.  (C, D) 
Morbidity and mortality after homologous influenza challenge. Groups of 
C56BL/6 mice were immunized with either 0.2 μg TIV, 0.2 μg TIV+ MVA-
NP+M1, or left unvaccinated. Six months following immunization animals were 
challenged intranasally with 1x10
4
 PFU of A/England/195/09 and monitored for 
weight loss and survival. (C) The average % weight loss per day per treatment 
group and (D) the survival curves up to day 14 post-challenge are shown. Curves 
are offset by 0.2 units to allow for ease of viewing.  Data are shown as mean of 7 










Figure 4. Ab responses to HA in mice, chickens, and pigs following MVA-
NP+M1 co-administration. Mice were immunized i.m. twice with either 10 µg H5 
HA A/Vietnam/1203/04 alone (H5 only) or H5 HA+ MVA-NP+M1 (H5+MVA). 
Vaccinations were administered via the mixed route three weeks apart. For 
chicken experiments, birds were either not primed (nil io) or primed io with 
AdHu5-NP+M1 1x10
9
 infectious units (Ad io) and boosted with either H7 HA 
A/Netherlands/219/03 alone (HA only), or H7 HA+MVA-NP+M1 (MVA+HA) at 
three weeks post-hatch. Naïve animals receiving no treatment served as controls 
(no treatment). Pigs were primed i.m. with 10 µg H5 HA (A/duck/Hunan/795/02), 
5 x10
10
 vp ChAdOx1-NP+M1, or 10 µg H5 HA+ ChAdOx1-NP+M1 (adjacent 
administration route). Four weeks later animals were boosted with either 10 µg 
H5 HA, 1.5 x 10
8 
PFU MVA-NP+M1, or 10 µg H5 HA+ MVA-NP+M1. 
For mice and pigs, total IgG titers were measured in the serum in response to H5 
HA by ELISA. Total IgY titers were measured to H7 HA by ELISA in chicken 
serum samples. (A) Time course of median IgG titers in mice for each treatment 
group. Data are shown as median + interquartile range for 5 animals and are 
representative of one experiment.  The dotted line indicates threshold for 
responses above background. *p<0.05, **p<0.01 by Mann-Whitney test. (B) T-
cell responses assayed by ex vivo IFN-γ ELISPOT in mouse splenocytes at 2 
weeks post 1
st
 immunization Cells were stimulated with H5 HA peptides; each 
symbol represents an individual mouse and bars represent medians.  Data shown 
are representative of one experiment.  **p<0.01 by Mann-Whitney test. (C) 
Median IgY levels in chickens against H7 HA by ELISA at all time points for all 
groups. Sera was pooled from 5 birds per immunization group.  The dotted line 
indicates threshold for responses above background. (D) T-cell responses assayed 
by ex vivo IFN-γ ELISPOT in chicken splenocytes at 10 days post-boost. Cells 
were stimulated with overlapping NP+M1 peptide pools. Each symbol represents 
an individual chicken and bars represent means.  Data shown are representative of 
one experiment *p<0.05 by one-way ANOVA with Tukey’s multiple comparison 
posttest. (E) Median H5 HA IgG titers in pigs at day 42 post-prime immunization. 
(F) T-cell responses assayed by ex vivo IFN-γ ELISPOT in pig PBMCs at the 
peak of the T-cell response (day 35 post-prime immunization). Cells were 
stimulated with overlapping NP+M1 peptide pools and responses to individual 
pools were summed for each animal. Each symbol represents an individual pig 
and bars represent medians.  Data shown are representative of one experiment.  




















Table 1  
      HAI responses to homologous TIV components at 2 weeks post-
immunization. 
              
 
HI Titer ≥ 20 
 
HI Titer ≥40 
  n %   n % 
0.2 ug TIV  
     A/CA/07/09 4/10 40 
 
0/10 0 
A/Perth/16/09 0/10 0 
 
0/10 0 
B/Brisbane/60/08 0/10 0 
 
0/10 0 
      0.2 ug TIV +MVA  
    A/CA/07/09 7/10 70 
 
4/10 40 
A/Perth/16/09 9/10 90 
 
6/10 60 













     HAI titers to influenza virus at 2 weeks post-
immunization. 
         
   
 
HAI titer, geometric mean (95% 
CI) 
   
  0.2 ug TIV 
0.2 ug TIV 
+MVA 
   








   A/Perth/16/09 15.2 (8.9-25.8) 52.8b (26-107.2) 
   B/Brisbane/60/08 N/A N/A 
         
   
      a Significantly different between 0.2 μg TIV and 0.2 ug TIV+MVA (p< 0.05 by Mann-Whitney U test) 
b Significantly different between 0.2 μg TIV and 0.2 ug TIV+MVA (p<0.01 by Mann-Whitney U test) 
N/A insufficient responses to calculate GM 












     Median inhibitory concentration (IC50) titers of mouse antisera against H5N1 lentiviral pseudotypes at 2 week post 2nd 
immunization.  
Mice were immunized twice with H5 HA from A/VN/1203/04 (clade 1) +/- MVA-NP+M1 (MVA) 
 
    
 
 
   
 
 
Homology IC50 Titers 
 
Lentiviral Pseudotype Clade 
% Amino Acid 
sequence 
identity 
H5 protein only H5+MVA 
 A/VN/1203/04 1 100 70 799
a
 
 A/IN/5/05 2.1.3.2 96.6 160 714
a
 
 A/AN/1/05  2.3.4 96.3 134 1372
a
 
 A/tk/Tk/1/05 2.2.1 96.1 188 1711
a
 













      Median inhibitory concentration (IC50) titers of pig antisera against H5N1 lentiviral pseudotypes at day 42 post-prime immunization 
Pigs were immunized twice with H5 HA from A/duck/Hunan/795/03 (Clade 2.1) +/- ChAdOx1-NP+M1 (ChAdOx1) or MVA-NP+M1 (MVA) 
       
      
   
 
  Homology IC50 Titers 
  
Lentiviral Pseudotype Clade 
% Amino acid 
sequence 
identity 
H5 protein only H5HA+ChAdOx1/H5HA+MVA 
  A/IN/5/05  2.1.3.2 98 918 2522
a
 
  A/HK/213/03  1 98 3533 8507
a
 
  A/tk/Tk/1/05 2.2.1 97.3 2964 8080
a
 
  A/VN/1203/04 1 97.1 1066 3076
b
 
  A/AN/1/05  2.3.4 97 1324 2944 
  a Significantly different between H5 only and H5HA+ChAdOX1/H5HA+MVA (p< 0.05 by Mann-Whitney U test) 
 b Significantly different between H5 only and H5HA+ChAdOx/H5HA+MVA (p< 0.01 by Mann-Whitney U test) 
  
 
